News & Updates
Filter by Specialty:
Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
SER-109, an investigational oral microbiome therapeutic, achieves superiority over placebo in reducing recurrent Clostridioides difficile infection (CDI) rates, according to updated findings from the phase III ECOSPOR-III trial.
Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
20 May 2022
COVID-19 vaccine hesitancy persists in pregnant women despite recommendations
Acceptance rates of COVID-19 vaccines have remained unchanged among unvaccinated pregnant women following national recommendations, with nearly one-third of patients seeing the vaccine as something harmful to their pregnancy, according to a study.
COVID-19 vaccine hesitancy persists in pregnant women despite recommendations
16 May 2022
Oral tebipenem pivoxil hydrobromide works against complicated UTI, acute pyelonephritis
Oral tebipenem pivoxil hydrobromide appears to be as good as intravenous ertapenem in the treatment of patients with complicated urinary tract infection (UTI) and acute pyelonephritis, with the two having a similar safety profile, according to data from a phase III study.
Oral tebipenem pivoxil hydrobromide works against complicated UTI, acute pyelonephritis
16 May 2022
Long-term aspirin use lowers HCC risk in chronic HBV patients
Use of aspirin in the long term appears to markedly reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV), a study has shown.
Long-term aspirin use lowers HCC risk in chronic HBV patients
14 May 2022
No apparent link between COVID-19 vax and cerebrovascular outcomes
Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.
